A study by the University of Cambridge and the Institute of Cancer Research London has identified significant gaps in the breast cancer risk assessment guidelines used by general practitioners in England. The findings, published in the British Journal of Cancer, indicate that the National Institute for Health and Care Excellence criteria currently employed to identify women requiring specialist evaluation or preventive care fail to detect the vast majority of younger patients who will subsequently develop breast cancer.
According to the analysis, current guidelines miss up to 95% of women under 50 who go on to develop the disease within 10 years. When researchers compared existing criteria against a new risk assessment system called Boadicea, developed by Cambridge and funded by Cancer Research UK, the alternative model identified eight times as many women in this age group at elevated risk. A primary reason for this discrepancy is that approximately 73% of women under 50 who develop breast cancer within 10 years have no family history of the disease, which represents a key component of the Nice guidelines.
The Boadicea system incorporates additional factors beyond family history, including reproductive history, lifestyle variables, and genetic information. Experts contend that earlier identification of higher-risk women could provide opportunities for additional screening and preventive interventions, potentially improving treatment outcomes or preventing disease development altogether. Dr Juliet Usher-Smith of the University of Cambridge emphasized the importance of refining risk identification methods to enable early intervention when more treatment options are available.
While researchers advocate for updated guidelines, stakeholders acknowledge the practical considerations involved. Prof Montserrat García-Closas noted that while current Nice criteria are simpler to implement, they miss a substantial proportion of at-risk women, whereas comprehensive assessments including genetic testing require significant resource investment. Breast Cancer Now, which supported the research, called for careful consideration of these findings as part of an ongoing Nice review, while emphasizing the need for adequate funding to implement any changes effectively across the NHS.
Nice responded by acknowledging the study’s potential value but stated that current evidence does not yet justify modifying existing guidelines. The organization indicated its commitment to reviewing additional evidence and considering future updates as more data on feasibility and clinical outcomes become available.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI